SCHEMBL16602337

SCHEMBL16602337

Cc1ccc(C(=O)Nc2ccc(-c3nc4ccccc4s3)c(Cl)c2)cc1C

nearest known ligand 0.75

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.75
▸ MAPT P10636 15/20 0.74
▸ TP53 P04637 4/20 0.74
▸ THRB P10828 1/20 0.74
▸ RXFP1 Q9HBX9 5/20 0.67
▸ POLB P06746 4/20 0.67
▸ LMNA P02545 1/20 0.60
▸ MEN1 O00255 3/20 0.55
▸ KMT2A Q03164 3/20 0.55
▸ KDM4E B2RXH2 1/20 0.55
▸ NPC1 O15118 1/20 0.55
▸ ALDH1A1 P00352 1/20 0.55
▸ HPGD P15428 1/20 0.55
▸ RAB9A P51151 1/20 0.55
▸ BLM P54132 1/20 0.55
▸ AGPAT2 O15120 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12963198 0.90 SMN1; SMN2 (0.70) SMN1; SMN2MAPTTP53THRBRXFP1
SCHEMBL12980863 0.88 SMN1; SMN2 (0.67) SMN1; SMN2MAPTTP53THRBRXFP1
SCHEMBL12963203 0.88 MAPT (0.83) SMN1; SMN2MAPTTP53THRBRXFP1
SCHEMBL12963207 0.85 SMN1; SMN2 (0.78) SMN1; SMN2MAPTTP53THRBRXFP1
SCHEMBL16602332 0.85 MAPT (0.82) SMN1; SMN2MAPTTP53THRBRXFP1
SCHEMBL1072473 0.85 MAPT (0.89) SMN1; SMN2MAPTTP53THRBRXFP1
SCHEMBL1071325 0.85 MAPT (0.79) SMN1; SMN2MAPTTP53THRBRXFP1
SCHEMBL12963278 0.83 MAPT (0.74) SMN1; SMN2MAPTTP53RXFP1POLB
SCHEMBL12980741 0.81 SMN1; SMN2 (0.65) SMN1; SMN2MAPTTP53THRBRXFP1
SCHEMBL1074520 0.79 TP53 (0.80) SMN1; SMN2MAPTTP53THRBRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150150852-A1 TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS SIGA TECHNOLOGIES, INC. (US) 2015-06-04 — — US disclosed
US-8993604-B2 Treatment and prevention of dengue virus infections SIGA TECHNOLOGIES, INC. (US) 2015-03-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150150852-A1 TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS HAVCR2, TTPA, CHIA SMN1; SMN2 814/4885MAPT 118/4885TP53 2739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback